Sustained Response to Anti-PD-1 Therapy in Combination with Nab-Paclitaxel in Metastatic Testicular Germ Cell Tumor Harboring the KRAS-G12V Mutation: A Case Report
To the best of our knowledge, this is the first successful case of KRAS-mutation patient with TGCT who achieved partially and sustained disease remission by combining immune checkpoint inhibitors with chemotherapy. This case provides an excellent example for personalized treatment of metastatic TGCTs.
Authors
- Wu Wei (ORCID: https://orcid.org/0000-0001-5200-3949)
- Yingzhi Chen (ORCID: https://orcid.org/0000-0002-8020-9810)
- Suying Wang (ORCID: https://orcid.org/0000-0002-5800-8035)
- Da Li (ORCID: https://orcid.org/0000-0003-0629-0742)
- Qi Ma (ORCID: https://orcid.org/0000-0002-5350-0362)
- Weiqi Yin
- Jin-feng Pan
- Hui Wang
Institutions
- Ningbo University (CN)
- University of Nottingham Ningbo China (CN)
- Sir Run Run Shaw Hospital (CN)
- Ningbo No. 2 Hospital (CN)
- Ningbo University Affiliated Hospital (CN)
- Spanish Oncology Genitourinary Group (ES)
- Ningbo First Hospital (CN)
Publication Details
- Journal
- Urologia Internationalis
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1159/000541588
- Citations
- 3
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.72